➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
McKinsey
Boehringer Ingelheim
Baxter
Harvard Business School

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

UROXATRAL Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Uroxatral patents expire, and when can generic versions of Uroxatral launch?

Uroxatral is a drug marketed by Concordia and is included in one NDA.

The generic ingredient in UROXATRAL is alfuzosin hydrochloride. There are nineteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the alfuzosin hydrochloride profile page.

Drug patent expirations by year for UROXATRAL
Drug Prices for UROXATRAL

See drug prices for UROXATRAL

Drug Sales Revenue Trends for UROXATRAL

See drug sales revenues for UROXATRAL

Recent Clinical Trials for UROXATRAL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
SanofiN/A
University Hospitals Cleveland Medical CenterN/A
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Phase 3

See all UROXATRAL clinical trials

Pharmacology for UROXATRAL
Paragraph IV (Patent) Challenges for UROXATRAL
Tradename Dosage Ingredient NDA Submissiondate
UROXATRAL TABLET, EXTENDED RELEASE;ORAL alfuzosin hydrochloride 021287 2007-06-12

US Patents and Regulatory Information for UROXATRAL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Concordia UROXATRAL alfuzosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021287-001 Jun 12, 2003 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for UROXATRAL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Concordia UROXATRAL alfuzosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021287-001 Jun 12, 2003   Start Trial   Start Trial
Concordia UROXATRAL alfuzosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021287-001 Jun 12, 2003   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
AstraZeneca
Harvard Business School
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.